newsfilter
← Latest News
ACCESS Newswire·

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS-7-derived CD3